Literature DB >> 12052484

Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects.

Helen M Colhoun1, Francesco Zito, N Norman Chan, Michael B Rubens, John H Fuller, Steve E Humphries.   

Abstract

The relationship of activated factor XII (FXIIa) and FXII 46C>T genotype to coronary atherosclerosis and endothelial function was examined in 192 randomly sampled subjects from the general population and 190 type 1 diabetic subjects (mean age 38+/-4 years). Coronary artery calcification (CAC) was measured using Electron beam CT. von Willebrand factor (vWF), a marker of endothelial function, and FXIIa were measured by ELISA. Endothelial nitric oxide production was quantified as the forearm blood flow response to intra-brachial infusion of bradykinin and N(G) monomethyl-L-arginine (L-NMMA). A higher FXIIa was independently associated with higher triglycerides (P<0.001), BMI (P=0.001), alcohol consumption (P=0.003) and vWF (P<0.001) in non-diabetic subjects and with insulin dose (P=0.009), total cholesterol (P=0.02) and alcohol (P<0.001) in diabetic subjects. Diabetic subjects had lower FXIIa (1.55 ng/ml) than non-diabetic subjects (1.92 ng/ml, P<0.001). Higher FXIIa was associated with lower response to bradykinin (P=0.048) and to L-NMMA (P=0.029). FXIIa was positively associated with CAC (odds ratio=1.57 for every 1 ng/ml higher FXIIa, P=0.005) but not independently of other risk factors (odds ratio=1.1 on adjustment). 46C>T genotype explained 18% of the variance in FXIIa (P<0.001) but was not associated with CAC (P=0.6). We conclude that plasma FXIIa is under strong genetic control but also reflects plasma triglycerides and endothelial activation or dysfunction. FXIIa appears unlikely to be directly atherogenic but may be a useful marker of coronary atherosclerosis because of its association with these other factors. Type 1 diabetes is associated with lower levels of FXIIa despite a greater prevalence of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12052484     DOI: 10.1016/s0021-9150(02)00022-9

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  16 in total

1.  Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials.

Authors:  G V Robinson; J C T Pepperell; H C Segal; R J O Davies; J R Stradling
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

2.  2013 scientific sessions Sol Sherry distinguished lecture in thrombosis: polyphosphate: a novel modulator of hemostasis and thrombosis.

Authors:  Stephanie A Smith; James H Morrissey
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-23       Impact factor: 8.311

3.  Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates.

Authors:  C Puy; E I Tucker; Z C Wong; D Gailani; S A Smith; S H Choi; J H Morrissey; A Gruber; O J T McCarty
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

Review 4.  Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.

Authors:  Evi Stavrou; Alvin H Schmaier
Journal:  Thromb Res       Date:  2010-03       Impact factor: 3.944

Review 5.  Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation.

Authors:  James H Morrissey; Sharon H Choi; Stephanie A Smith
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

6.  Why do we want to know how factor XII levels are modulated?

Authors:  Alvin H Schmaier
Journal:  Thromb Res       Date:  2009-10-21       Impact factor: 3.944

7.  Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIa.

Authors:  Peter C Papageorgiou; Demetrios Simos; Frans Boomsma; Rasmus Rojkjaer; Daniel H Osmond
Journal:  Can J Cardiol       Date:  2009-04       Impact factor: 5.223

Review 8.  Polyphosphate: a new player in the field of hemostasis.

Authors:  Stephanie A Smith; James H Morrissey
Journal:  Curr Opin Hematol       Date:  2014-09       Impact factor: 3.284

9.  Possible role of new pressor protein in hypertensive anephric hemodialysis patients.

Authors:  Rachel J Pearl; Peter C Papageorgiou; Michael Goldman; Akis A Amfilochiadis; Frans Boomsma; Rasmus Rojkjaer; Denis Geary; Daniel H Osmond
Journal:  Pediatr Nephrol       Date:  2003-08-12       Impact factor: 3.714

Review 10.  Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system.

Authors:  Alvin H Schmaier
Journal:  Int Immunopharmacol       Date:  2007-09-05       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.